Monopar Therapeutics Management
Management criteria checks 2/4
Monopar Therapeutics' CEO is Chandler Robinson, appointed in Dec 2014, has a tenure of 9.92 years. total yearly compensation is $1.78M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 1.09% of the company’s shares, worth €884.49K. The average tenure of the management team and the board of directors is 5.7 years and 8.8 years respectively.
Key information
Chandler Robinson
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 32.6% |
| CEO tenure | 9.9yrs |
| CEO ownership | 1.1% |
| Management average tenure | 5.7yrs |
| Board average tenure | 8.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$6m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$2m | US$580k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$2m | US$550k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$10m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | US$1m | US$525k | -US$9m |
| Sep 30 2021 | n/a | n/a | -US$9m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$7m |
| Dec 31 2020 | US$2m | US$504k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$5m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | US$541k | US$386k | -US$4m |
| Sep 30 2019 | n/a | n/a | -US$4m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$1m | US$375k | -US$3m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Jun 30 2018 | n/a | n/a | -US$17m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | US$401k | US$331k | -US$17m |
Compensation vs Market: Chandler's total compensation ($USD1.78M) is above average for companies of similar size in the German market ($USD483.03K).
Compensation vs Earnings: Chandler's compensation has increased whilst the company is unprofitable.
CEO
Chandler Robinson (40 yo)
9.9yrs
Tenure
US$1,778,655
Compensation
Dr. Chandler D. Robinson, M.D., MBA, MSc, Co-Founded Monopar Therapeutics Inc. in 2010 and has been Chief Executive Officer and Director since December 2014 and serves as President. Among his previous expe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Executive Chairman of the Board | 9.9yrs | US$264.04k | 0.29% € 237.1k | |
| Co-Founder | 9.9yrs | US$1.78m | 1.09% € 884.5k | |
| Chief Operating Officer | 3.4yrs | US$911.14k | 0.78% € 627.9k | |
| CFO, Principal Accounting Officer & Principal Financial Officer | less than a year | no data | 0.030% € 24.4k | |
| Acting Chief Medical Officer | 7.9yrs | no data | no data |
5.7yrs
Average Tenure
53yo
Average Age
Experienced Management: 1IY0's management team is seasoned and experienced (5.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Executive Chairman of the Board | 9.9yrs | US$264.04k | 0.29% € 237.1k | |
| Co-Founder | 9.9yrs | US$1.78m | 1.09% € 884.5k | |
| Independent Director | 9.9yrs | US$126.04k | 0.92% € 742.9k | |
| Independent Director | 7.6yrs | US$136.54k | 0.10% € 84.6k | |
| Independent Director | 7.3yrs | US$128.54k | 0.12% € 97.2k | |
| Director | 1.7yrs | US$848.44k | 0.22% € 180.9k |
8.8yrs
Average Tenure
65.5yo
Average Age
Experienced Board: 1IY0's board of directors are considered experienced (8.8 years average tenure).